How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics, Inc. (NASDAQ:AKCA) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The business earned $22.38 million during the quarter, compared to the consensus estimate of $30.93 million. Akcea Therapeutics had a negative net margin of 12.34% and a negative trailing twelve-month return on equity of 8.94%. The firm's revenue was down 15.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS.

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS) , Intelsat (I) , Bank of America (BAC) , Fossil Group (FOSL) , Achaogen (AKAO) , Ciena (CIEN) , AMC Entertainment (AMC) , Advanced Micro Devices (AMD) , Apollo Global Management (APO) and Exelixis (EXEL) .

When did Akcea Therapeutics IPO?

Akcea Therapeutics (AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free AKCA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $18.17
▼
$18.17
50-Day Range: $18.13
▼
$18.17
52-Week Range: $8.00
▼
$21.70

Volume: N/A
Average Volume: 361,806 shs
Market Capitalization: $1.85 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Akcea Therapeutics alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Ad DTI

This company has increased its dividend every year for 54 years

Click here to get them (for Free).

AKCA Stock News Headlines

January 6, 2024 | morningstar.com

Arcturus Therapeutics Holdings Inc ARCT

September 27, 2023 | investing.com

AKCA Historical Data

April 19, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

January 5, 2022 | investing.com

Akcea Therapeutics Inc (AKCA)

October 26, 2021 | finance.yahoo.com

Akcea Therapeutics to Present at Upcoming Investor Conferences

See More Headlines

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/04/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AKCA
CUSIP: N/A
CIK: 1662524
Web: www.akceatx.com
Phone: 617-207-0202
Fax: N/A
Employees: 248
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.48
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $40.77 million
Net Margins: -12.34%
Pretax Margin: N/A
Return on Equity: -8.94%
Return on Assets: -8.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.17
Quick Ratio: 11.78

Sales & Book Value

Annual Sales: $488.54 million
Price / Sales: 3.78
Cash Flow: $0.51 per share
Price / Cash Flow: 35.54
Book Value: $5.78 per share
Price / Book: 3.14

Miscellaneous

Outstanding Shares: 101,599,000
Free Float: N/A
Market Cap: $1.85 billion
Optionable: Optionable
Beta: 1.45

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Ms. Paula Soteropoulos (Age 51)
CEO & Director
Mr. Michael F. MacLean (Age 53)
Chief Financial Officer
Dr. Louis St. Laurence O'Dea FRCPC (Age 68)
MB, BCh, BAO, FRCP(C), Chief Medical Officer
Ms. Sarah Boyce (Age 47)
Pres & Director
Mr. Jeffrey M. Goldberg (Age 46)
Chief Operating Officer

Key Competitors

View All Competitors

AKCA Stock Analysis - Frequently Asked Questions

How were Akcea Therapeutics' earnings last quarter?: Akcea Therapeutics, Inc. (NASDAQ:AKCA) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The business earned $22.38 million during the quarter, compared to the consensus estimate of $30.93 million. Akcea Therapeutics had a negative net margin of 12.34% and a negative trailing twelve-month return on equity of 8.94%. The firm's revenue was down 15.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS.
What other stocks do shareholders of Akcea Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Advanced Micro Devices (AMD), Apollo Global Management (APO) and Exelixis (EXEL).
When did Akcea Therapeutics IPO?: Akcea Therapeutics (AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

This page (NASDAQ:AKCA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

About Akcea Therapeutics Stock (NASDAQ:AKCA)

AKCA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AKCA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info